D. Debabov

Journal of Antimicrobial Chemotherapy, Antimicrobial Agents and Chemotherapy, Microbiology spectrum
4
Role Title Level Year L/R
🐜 Efficacy and safety of ceftazidime/avibactam in patients with infections caused by β-lactamase-producing Gram-negative pathogens: a pooled analysis from the Phase 3 clinical trial programme
10 auth. AntonΓ­ Torres, M. Wible, M. Tawadrous, P. Irani, G. Stone, Alvaro Quintana, ... D. Debabov, Margaret Burroughs, P. A. Bradford, Marin H. Kollef 		3 2023 3
🐜
🐬 Antimicrobial Activity of Ceftazidime-Avibactam and Comparators against Pathogens Harboring OXA-48 and AmpC Alone or in Combination with Other β-Lactamases Collected from Phase 3 Clinical Trials and an International Surveillance Program
L. Lin, D. Debabov4, W. Chang, G. Stone, Todd Riccobene 		2 2022 2
🐬
🐜 Real-world in vitro activity of newer antibiotics against Enterobacterales and Pseudomonas aeruginosa, including carbapenem-non-susceptible and multidrug-resistant isolates: a multicenter analysis
7 auth. Todd Riccobene, Chin-En Ai, Kalvin C. Yu, Sara Gregory, Brooke Kim, D. Debabov, ... Vikas Gupta 		1 2023 1
🐜
🦁 Low Frequency of Spontaneous Resistance and Low Potential for Cross-Resistance to N,N -dichloro-2,2-dimethyltaurine (NVC-422)
D. Debabov4 		0 2008 0
🦁